Lilly’s tirzepatide challenges semaglutide in obesity drug market
This head-to-head comparison pits Lilly’s Zepbound (tirzepatide) against Novo Nordisk’s Wegovy (semaglutide) at a time when the obesity drug market is experiencing explosive growth.
Business Industrial